Government caps trade margins on 137 anti-cancer drugs at 30%
The government has capped the trade margins on 137 anti-cancer drugs at 30%, including several patented medicines such as pembrolizumab, ribociclib and abemaciclib. The manufacturers were asked to submit revised Maximum Retail Prices (MRP) to the National Pharmaceutical Pricing Authority (NPPA) within seven days. The new MRP will come into effect from November 9, 2026, and will remain in force until further orders.
It is expected that the new prices will reduce MRP broadly in the range of 20-70%, resulting in annual savings of approximately ₹2,500 crore. The government's move aims to address the high mark-ups on non-scheduled cancer drugs, which can be as high as 700%.
Written by urgent.news from The Indian Express - India's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
